IBAC · XBRL financial data
IB Acquisition financial statements, every quarter
The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (IBAC's year ends in late September)
| In thousands of dollars | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| General and administrative | 195 | 76 | 165* | 176 | 163 | 172 | 237* | 180 | 748 | 624 |
| Operating income (loss) | (195) | (76) | (165)* | (176) | (163) | (172) | (237)* | (180) | (748) | (624) |
| Interest income | — | 1,505 | — | 1,372 | 1,250 | 1,254 | — | — | — | — |
| Interest expense | — | (1,505) | (1,522)* | — | — | — | — | — | — | — |
| Income tax expense (benefit) | — | 315 | 321* | 288 | 263 | 263 | 152* | 32 | 29 | 15 |
| Net income (loss) | (195) | 1,113 | 1,036* | 907 | 824 | 819 | 866* | (59) | (640) | (567) |
Balance sheet
CSVFiscal quarters (IBAC's year ends in late September)
| In thousands of dollars | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1,661 | 877 | 823 | 910 | 627 | 486 | 429 | 165 | 5 | 30 |
| Total current assets | 1,690 | 1,236 | 1,199 | 1,173 | 865 | 623 | 1,244 | 362 | 288 | 257 |
| Total assets | 117,265 | 118,394 | 119,800 | 120,832 | 121,164 | 122,177 | 17,134 | 16,405 | 8,477 | 8,518 |
| Accrued liabilities | 337 | 38 | — | — | — | — | — | — | — | — |
| Total current liabilities | 337 | 352 | 722 | 846 | 355 | 549 | 1,832 | 1,162 | 1,840 | — |
| Total liabilities | 337 | 352 | 722 | 846 | 355 | 549 | 1,832 | 1,162 | 1,840 | 2,447 |
| Retained earnings (accumulated deficit) | (291) | 823 | 1,111 | 935 | 771 | 599 | (682) | (862) | (1,689) | (2,313) |
| Total stockholders' equity | 1,354 | 1,277 | 1,112 | 935 | 772 | 600 | (681) | (861) | (1,688) | (2,312) |
| Total liabilities and equity | 117,265 | 118,394 | 119,800 | 120,832 | 121,164 | 122,177 | 17,134 | 16,405 | 8,477 | 8,518 |
| Common shares outstanding (cover page) thousands of shares | 15,749 | 15,749 | 15,749 | 15,749 | 15,749 | 15,749 | 5,740 | 5,740 | 5,008 | 5,008 |
Cash flows
CSVFiscal quarters (IBAC's year ends in late September)
| In thousands of dollars | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (195) | 1,113 | 1,036* | 907 | 824 | 819 | 866* | (59) | (640) | (567) |
| Net cash from operating activities | (104)* | (585)* | (54)* | (375) | (744)* | (141)* | (57)* | (1,051) | (266)* | (474)* |
| Net cash from investing activities | — | 0* | 0* | 315 | 609* | 0* | 106,918* | — | — | 0* |
| Share repurchases | — | — | — | — | — | — | year only | — | — | 0* |
| Net cash from financing activities | 117,160* | (199)* | 0* | 148 | — | — | year only | — | — | 500* |
Compare with peers
SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| IB Acquisition | 30 | not reported | (474)* | 5.0M | 0.1 quarters | 10-QJun 30, 2026 |
| OneMedNet | 358 | 292 | (1,875)* | 59.3M | 0.2 quarters | 10-QJun 30, 2026 |
| bioAffinity Technologies | 2,430 | 1,511 | (3,201)* | 8.1M | 0.8 quarters | 10-QJun 30, 2026 |
| Inotiv | 15,180 | 117,652 | (1,070)* | 34.9M | 14.2 quarters | 10-QMar 31, 2026 |
| Hypha Labs | 5.1 | not reported | (52)* | 163.9M | 0.1 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.